Boston Scientific Corporation (BSX) M&A Call Transcript

Operator

Good morning, and welcome to the Boston Scientific Investor Update. [Operator Instructions] Please note this event is being recorded. I would now like to turn the conference over to Lauren Tengler, Vice President, Investor Relations. Please go ahead.

Lauren Tengler
Director of Investor Relations

Thank you, Drew, and thank you, everyone, for joining us today. With me are Mike Mahoney, Chairman and Chief Executive Officer; Jon Monson, Executive Vice President and Chief Financial Officer; and Adam Elsesser, Chairman and Chief Executive Officer of Penumbra. During the Q&A session, Mike, Jon and Adam will be joined by Joe Fitzgerald, Executive Vice President and Group President, Cardiovascular; and Dr. Michael R. Jaff, [ Vice President, Peripheral ] Interventions, Chief Medical Officer. We issued a press release earlier this morning announcing that we have entered into an agreement to acquire Penumbra. The release, along with a presentation describing the acquisition can be found on the Investor Relations section of our website.

This call contains forward-looking statements regarding, among other things, the anticipated financial and business impact and benefits of the